« Canada Recalls Prexige from Market | Main | Tentative FDA Approval for Generic Zyrtec Chewable »

Oct 5
GlaxoKlein and Merck's PR Battle of the HPV Vaccines

For the last week or so pharma news has been full of articles headlining either GlaxoSmithKlein's (NYSE:GSK) Cervarix or Merck's (NYSE:MRK) Gardasil. Both are vying for the bigger share of the potential multi-billion cervical cancer pot.

It started with GlaxoSmithKlein submitting for marketing approval of Cervarix in Japan, switched to Merck donating 3 million doses of Gardasil to developing countries and went back to Glaxo starting sales in Europe and requesting prequalification from WHO for distribution in developing countries. Then we had Merck winning the Prix Galien for best new biotech product and Sanofi Pasteur filing to extend Gardasil treatments in Europe.

HPV%20VAccine.jpgNow all this battling is interesting on the heels of other information. First, researchers are now studying the HPV vaccine in boys and some are suggesting mass vaccinations of boys. Secondly, there is new research that suggests that HPV is linked to about half of a certain type of throat tumors. Thirdly, there is a huge push to have all girls vaccinated and a smaller push to have boys included in the vaccination program. Add in that cervical cancer is the second leading cause of cancer deaths around the world and it's pretty easy to see why these 2 companies are ready to go to media "war" to put their product forefront in the minds of consumers.

For a great article about the background of the HPV vaccine and the cultural implications of mandatory vaccinations check out: Cultural Advocacy and the HPV Vaccine.

And here's an article from McLean's Canada called: Our Girls are not Guinea Pigs and another article with a little more emotion: HPV Vaccine Debate Plagued by Ignorant Opposition.


1 Comments/Trackbacks




» Merck's Gardasil for HPV Protects Older Women Also from PharmaGazette
Merck & Co. (NYSE:MRK) released a study that its Gardasil HPV (human papillomavirus) vaccine may offer protection to women over the current FDA approved age range of 9 to 26.The study, which consisted of 3,800 women between the ages of... [Read More]

submit a trackback

TrackBack URL for this entry:

post a comment

Name, Email Address, and URL are not required fields.





Comment Preview

« Canada Recalls Prexige from Market | Main | Tentative FDA Approval for Generic Zyrtec Chewable »

Advertise

Watch the Digital Health Revolution


sponsored ads



subscribe


Prefer Email?
Subscribe below-

Enter your Email:


Powered by FeedBlitz What's this?

Current News

Support This Blog

top blogs

business social media

Use these fast growing business social media sites to promote your business, feature your products, spotlight your business leaders, create links, and drive traffic back to your company site, all for free!

BIZZlogos - Add your logo - free link to your site
BIZZphotos - Add photos of your products and people
BIZZprofiles - Submit your profile and build your online visibility
BIZZspotlight - Spotlight your business with free links
BIZZvideos - Videos about businesses, products and business people.
BIZZbites - "Digg" for Business - Submit your articles and posts

Know More Media - Health Care / Pharmaceutical / Fitness

know more media network

View Network Map

Network Feed List (OPML)

Know More Media Network
Feed


we support unitus

PRWeb

Influencer



PharmaGazette is a member of the Know More Media network of business related blogs.

Here are some current headlines from some of our business publications:

ProductivityGoal

CallCenterScript

AdHurl

TheBizofKnowledge

LandingTheDeal

CustomersAreAlways

HealthCareVox

BrainBasedBusiness

TheInsurancePolicy

MarketingBlurb